Ascletis Pharma Inc.

About Us
Corporate Overview Management Team Board of Directors Contact Us
Our Focus
Viral Diseases NASH/PBC Cancer Exploratory Indications
Products&Pipeline
Pipeline Products Clinical Trials
Partnership
Investors
Financials & Filing Presentation Materials
News
Careers

Investors

Financials & Filing
Presentation Materials

Voluntary Announcement - Gannex Published Phase I Data of ASC42, A Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
2023-11-06
Next Day Disclosure Returns - Share Buyback
2023-11-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
2023-11-03
Next Day Disclosure Returns - Share Buyback
2023-11-02
Next Day Disclosure Returns - Share Buyback
2023-11-01
Next Day Disclosure Returns - Share Buyback
2023-10-31
Next Day Disclosure Returns - Share Buyback
2023-10-30
Next Day Disclosure Returns - Share Buyback
2023-10-27
Next Day Disclosure Returns - Share Buyback
2023-10-26
Next Day Disclosure Returns - Share Buyback
2023-10-25

3

© 2018 Ascletis Pharma Inc.

All Rights Reserved

contact

pr@ascletis.com
bd@ascletis.com

hr@ascletis.com
clinicaltrials@ascletis.com

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1